In this Exclusive Interview, Sam Engel talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about diabetes drugs in the pipeline at Merck; clinical trials on sitagliptin and ertugliflozin, including the CompoSIT and VERSIS studies; and the problem of "clinical inertia" in intensifying treatment.

In this Exclusive Interview transcript, Sam Engel talks with Diabetes in Control Publisher Steve Freed during the ADA 2018 convention in Orlando about how clinical inertia affects diabetes treatment; clinical trials on sitagliptin and ertugliflozin, including the CompoSIT and VERSIS studies; and diabetes drugs in the Merck pipeline.

In addition, high-fat, low-carb breakfast tied to less hunger later in the day

Improvement seen in some self-reported health behaviors but not clinical health markers, health care utilization

But no significant differences seen in gestational DM risk between metformin users, nonusers

Risk for developing pediatric diabetes increased in offspring from birth through age 22 years

Labeling would result in gain in quality-adjusted life-years and health care and societal cost savings

Reductions seen in risk for kidney failure, cardiovascular disease with canagliflozin versus placebo

While driving from Palm Harbor to St. Petersburg last week I was looking at the proliferation of digital billboards. It seems like there were more of them on the 35 mile drive than Best Buy had TVs on display.  The cool thing about these is that about every 25 seconds …

Combination treatment can help improve glucose levels in patients with elevated HbA1Cs.